Virpax Pharmaceuticals Inc.
13F holders, Q1 2024 (March 31)5holders
$3.25avg. 13F price*
At the end of Q1 2024, 5 institutions reported holding Virpax Pharmaceuticals Inc. in their 13F filings. The largest holders were Tower Research Capital LLC (TRC) ($6K), Signature Resources Capital Management, LLC ($160) and Morgan Stanley ($64).
- Company
- Virpax Pharmaceuticals Inc.
- CUSIP
- 928251206
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $6K |
| Exits | 0 | $0 |
Ownership 5 holders
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,449 | $6K |
| Signature Resources Capital Management, LLC | 0.00% | New | 500 | $160 |
| Morgan Stanley | 0.00% | New | 15 | $64 |
| Wells Fargo & Company | 0.00% | New | 8 | $34 |
| Hantz Financial Services, Inc. | 0.00% | New | 10 | $0 |
"% of holder's portfolio" is VIRPAX PHARMACEUTICALS INC's weight in each manager's 13F, not the share of Virpax Pharmaceuticals Inc. the manager owns.